Different types of disease-driving antibodies tend to associate with different symptoms of eosinophilic granulomatosis with polyangiitis (EGPA), the rarest form of ANCA-associated vasculitis. That’s according to the study “Spectrum of ANCA-specificities in eosinophilic granulomatosis with polyangiitis. A retrospective multicenter study,” published in Clinical and Experimental Rheumatology.
Urine levels of scarring, inflammation, and kidney damage biomarkers accurately reflect kidney biopsy results and predict kidney outcomes in people with ANCA-associated vasculitis (AAV), a pilot study suggests. According to its researchers, noninvasive urine tests could be used to monitor tissue or functional changes in the kidneys. Also, urinary…
The incidence of ANCA-associated vasculitis (AAV) in southern Sweden was stable over a 23-year period, while its prevalence, the total number of cases overall, increased, a study showed. Stable incidence, or the same number of new cases per year, with a higher prevalence “might indicate better management and treatment…
A specific variant in both copies of the gene that codes for proteinase 3 (PR3) — one of the most common targets of ANCA-associated vasculitis (AAV)-driving antibodies — is linked to a nearly five times higher risk of severe relapse in people with PR3-associated AAV, a study found. While…
Women carrying a genetic mutation dubbed rs9274619 have a significantly higher risk of ANCA-associated vasculitis (AAV) associated with antibodies against myeloperoxidase (MPO) than men, a new study shows. Among MPO-AAV patients, this mutation was linked to a greater likelihood of eye involvement and a lower risk of lung involvement.
Maintenance therapy with immunosuppressive agents such as rituximab and azathioprine do not increase the frequency of serious infections beyond what’s expected in people with ANCA-associated vasculitis (AAV), according to a new review study. Regardless of the medication used, fatal infections were uncommon during the maintenance therapy period, data…
ANCA-associated vasculitis (AAV) patients undergoing dialysis for kidney failure have a lower risk of relapse, but a higher risk of infection and death, according to a review study. These findings help piece together evidence “to provide guidance for managing these patients and to guide future research opportunities,” researchers wrote.
People with relapsing ANCA-associated vasculitis (AAV) who achieved remission with rituximab and glucocorticoids have less than half the risk of experiencing a new relapse if they continue on rituximab treatment than if they start daily oral azathioprine. That’s according to the full results of the Phase 3…
ANCA-associated vasculitis (AAV) patients with proteinuria, elevated protein levels in their urine, after induction treatment are at a three times higher risk of kidney failure and/or death, according to a study based on data from five clinical trials. Data also linked persistent hematuria, or blood in the urine, after…
The European Alliance of Associations for Rheumatology (EULAR) has updated its recommendations on managing ANCA-associated vasculitis (AAV) based on new research and clinical data. Four overarching principles were introduced — the importance of patient-physician joint decisions, disease education, routine screening for treatment side effects and additional medical conditions,…
Get regular updates to your inbox.